title: The TITAN trial--assessing the efficacy and safety of an anti-von Willebrand factor Nanobody in patients with acquired thrombotic thrombocytopenic purpura.
abstract: The Phase II TITAN trial is designed to assess the efficacy and safety of an anti-von Willebrand factor (vWF) Nanobody in patients with acquired thrombotic thrombocytopenic purpura (TTP). Nanobodies are a novel class of therapeutic proteins and are based on the smallest functional fragments of single-chain antibodies that occur naturally in the Camelidae family (Nanobody® and Nanobodies® are registered trademarks of Ablynx NV). With vWF implicated in the thrombotic process underlying TTP, an anti-vWF Nanobody may hold significant promise as adjunctive therapy to plasma exchange. Recruitment is currently ongoing, and aims to include a total of 110 patients from countries in Europe, the Middle East, Australia and Northern America.
authors.affiliation: Ablynx NV, Technologiepark 21, 9052 Zwijnaarde, Belgium. Josi.Holz@Ablynx.com
authors.forename: Josefin-Beate
authors.initials: JB
authors.lastname: Holz
mesh_terms: D000328:Adult; D000818:Animals; D002161:Camelids, New World; D005260:Female; D006801:Humans; D008297:Male; D010951:Plasma Exchange; D011697:Purpura, Thrombotic Thrombocytopenic / Q000628:therapy*; D057127:Single-Chain Antibodies / Q000008:administration & dosage* / Q000009:adverse effects; D014841:von Willebrand Factor / Q000037:antagonists & inhibitors*
chemical_list: D057127:Single-Chain Antibodies; D014841:von Willebrand Factor